A recent study published in JAMA Oncology evaluated the effectiveness of the 9-valent human papillomavirus vaccine in reducing cancer risk in males. The study included 615,155 vaccinated and 2,290,623 unvaccinated males aged 9 to 26 years, with follow-up of up to 10 years. Compared with unvaccinated individuals, vaccinated males showed a lower risk of HPV-related cancers, including head and neck, esophageal, anal, and penile cancers (HR 0.54). Age-based analysis showed a similarly reduced incidence in those aged 9 to 14 years (HR 0.58) and 15 to 26 years (HR 0.50).
These findings suggest that the 9-valent HPV vaccine is associated with a reduced risk of HPV-related cancers in males and support sex-neutral HPV vaccination strategies. How do these findings influence your view on sex-neutral HPV vaccination policies? ##Reference## Kitano T, Yoshida S. Nine-Valent Human Papillomavirus…
